Loading...
Market
How will Zepbound price reduction impact patient access by end of 2024?
2
Resolution / Starting Odds
Significant increase in patient access • 25%
Moderate increase in patient access • 25%
No significant change in patient access • 25%
Decrease in patient access • 25%
Reports from healthcare research firms and Eli Lilly's own data releases
Story
Eli Lilly Cuts Zepbound Price by 50%, Impacting Hims Stock and Earning Biden's Praise
Aug 27, 2024, 03:28 PM
Eli Lilly has announced a significant price reduction for its weight-loss drug Zepbound, now offering single-dose vials at a 50% discount. This move aims to expand access to the drug, particularly for patients without insurance coverage. The discounted vials are available through Lilly's direct-to-consumer platform, LillyDirect, with prices set at $399 for a four-week supply of the 2.5 mg dose and $549 for the 5 mg dose. This initiative is part of Eli Lilly's strategy to address supply shortages and increase the availability of Zepbound amid rising demand. The price cut poses a challenge to telehealth companies that offer compounded versions of the medication. In response to the announcement, shares of Hims & Hers Health fell, reflecting the competitive impact of Lilly's strategy. Additionally, President Biden praised the price reduction as a positive step towards making medications more affordable.
View original story
Similar markets
0-25% reduction • 25%
26-50% reduction • 25%
51-75% reduction • 25%
76-100% reduction • 25%
Less than 1 million • 25%
1 million to 2 million • 25%
2 million to 3 million • 25%
More than 3 million • 25%
Less than 100,000 • 25%
100,000 to 200,000 • 25%
200,000 to 300,000 • 25%
More than 300,000 • 25%
Approved in US only • 33%
Approved in US and one other major market • 33%
Approved in US and multiple other major markets • 33%
Cost decreases significantly • 25%
Cost decreases slightly • 25%
Cost remains the same • 25%
Cost increases • 25%
Less than $1 billion • 25%
$1 billion to $2 billion • 25%
$2 billion to $3 billion • 25%
More than $3 billion • 25%
